Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.
• Combining the Renal Angina Index and measurement of urinary Neutrophil Gelatinase Associated Lipocalin can improve predictions of severe acute kidney injury in critically ill children. • Results from the study will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
• Patients receiving hemodialysis at facilities located in residential areas with a high percentage of Black residents have a higher rate of hospitalization. • Results from the study will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
• Rates of kidney injury in women who are hospitalized during pregnancy are on the rise, especially in women with diabetes. • Results from the study will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
The American Society of Nephrology (ASN) will honor leaders in the fight against kidney disease during ASN Kidney Week 2019, the society’s annual meeting, held November 5–10 at the Walter E. Washington Convention Center in Washington, DC.
• Peritoneal dialysis performed with an automated wearable artificial kidney was safe and effective for removing toxins from the blood of patients with kidney failure. • Results from the study will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
• Few patients who start urgent and unplanned dialysis in clinical centers switch to home dialysis. The potential survival benefits of switching are unclear. • Results from the study will be presented at ASN Kidney Week 2019 November 5–November 10 at the Walter E. Washington Convention Center in Washington, DC.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right